Home207940 • KRX
add
Samsung Biologics Co Ltd
Nakaraang pagsara
₩1,514,000.00
Sakop ng araw
₩1,514,000.00 - ₩1,533,000.00
Sakop ng taon
₩982,000.00 - ₩1,987,000.00
Market cap
70.73T KRW
Average na Volume
43.37K
P/E ratio
41.25
Dividend yield
-
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (KRW) | Mar 2026info | Y/Y na pagbabago |
|---|---|---|
Kita | 1.26T | -3.18% |
Gastos sa pagpapatakbo | 99.00B | -58.99% |
Net na kita | 469.00B | 24.88% |
Net profit margin | 37.31 | 28.97% |
Kita sa bawat share | — | — |
EBITDA | — | — |
Aktuwal na % ng binabayarang buwis | 26.83% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (KRW) | Mar 2026info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 1.62T | 26.05% |
Kabuuang asset | 12.00T | -31.21% |
Kabuuang sagutin | 4.07T | -33.86% |
Kabuuang equity | 7.92T | — |
Natitirang share | — | — |
Presyo para makapag-book | — | — |
Return on assets | 12.60% | — |
Return on capital | 16.88% | — |
Cash Flow
Net change in cash
| (KRW) | Mar 2026info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 469.00B | 24.88% |
Cash mula sa mga operasyon | — | — |
Cash mula sa pag-invest | — | — |
Cash mula sa financing | — | — |
Net change in cash | — | — |
Malayang cash flow | — | — |
Tungkol
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
CEO
Itinatag
2011
Website
Mga Empleyado
4,770
